Methotrexate Ebewe Pharma (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for producing tetrahydrofolate. This limits the synthesis of thymidine and purine nucleotides, reducing DNA replication in rapidly dividing cells. The drug also increases extracellular adenosine, contributing to its anti‑inflammatory effects.

The prescribed dose of methotrexate is individualized by the treating physician based on the specific indication, patient weight, renal and hepatic function, and treatment goals. Dosing regimens vary widely between rheumatologic and oncologic uses, and the prescriber sets the exact schedule.

Methotrexate is classified as Pregnancy Category X because it is highly teratogenic and can cause fetal loss or birth defects. It is contraindicated during pregnancy and not recommended while breastfeeding, as it can be excreted in breast milk and harm the infant.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

For rheumatoid arthritis, methotrexate is often the first‑line disease‑modifying antirheumatic drug, whereas biologic agents target specific cytokines and are used when methotrexate alone is insufficient. In oncology, methotrexate is a conventional cytotoxic agent, while newer targeted therapies act on specific molecular pathways.

Methotrexate injectable solution should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture and direct light. Do not freeze. Follow standard aseptic handling procedures when preparing doses for administration.

Methotrexate is given by intra‑arterial, intramuscular, or intravenous injection, depending on the clinical indication and dosing schedule. The route and infusion rate are determined by the prescribing clinician, and the medication must be administered by qualified healthcare personnel in a controlled setting.

Serious risks include bone‑marrow suppression leading to pancytopenia, severe liver injury or fibrosis, and pulmonary toxicity such as interstitial pneumonitis. Patients should be monitored regularly for blood counts, liver function tests, and respiratory symptoms, and any alarming changes should prompt immediate medical evaluation.

Methotrexate is contraindicated in pregnant women, individuals with severe renal or hepatic impairment, active infections, and those with known hypersensitivity to the drug. Caution is also advised for patients with pre‑existing lung disease or a history of alcohol misuse.